Advertisement
Organisation › Details
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden. *
Start | 0199-01-01 established | |
Industry | cancer drug | |
Industry 2 | DRUGS, VETERINARY | |
Person | Martelet, Francois R. (Oasmia 202008 CEO before TopoTarget 201011 CEO) | |
Person 2 | af Winklerfelt, Michael (Oasmia 202008 CFO) | |
Region | Uppsala | |
Country | Sweden | |
Street | 1 Vallongatan | |
City | 72528 Uppsala | |
Tel | +46-18-505440 | |
Address record changed: 2021-10-26 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Oasmia Pharmaceutical AB
- [1] Oasmia Pharmaceutical AB. (9/8/20). "Press Release: Oasmia Pharmaceutical Appoints Fredrik Järrsten as Chief Financial Officer". Uppsala....
- [2] Oasmia Pharmaceutical AB. (8/10/20). "Press Release: Oasmia Pharmaceutical Appoints Peter Selin as Chief Business Officer". Uppsala....
- [3] Oasmia Pharmaceutical AB. (11/30/17). "Press Release: Oasmia Has Completed a Private Placement of New Convertible instruments in a Total Amount of SEK 28,000,000"....
- [4] Oasmia Pharmaceutical AB. (3/3/17). "Press Release: Interim Report for the Period May 2016 – January 2017. Strategic Changes within Animal Health Division". Uppsala....
- [5] Oasmia Pharmaceutical AB. (3/1/17). "Press Release: Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors". Upp...
- [6] Oasmia Pharmaceutical AB. (2/28/17). "Press Release: Oasmia Pharmaceuticals Chairman Anders Lönner Resigns". Uppsala....
- [7] Oasmia Pharmaceutical AB. (1/23/17). "Press Release: Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division". Uppsala....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top